FDA approves new drug to fight hepatitis C

Side effects with the three-drug regimen including anemia, nausea, headaches and problems with taste.Hepatitis C is a silent killer because infected individuals may go for years without showing symptoms before liver damage becomes apparent. This damage may take the form of cirrhosis, which is also related to bleeding, jaundice and liver cancer, too. According to the CDC, chronic hepatitis C is responsible for liver transplants today, most conducted in the United States.

The FDA approved Victrelis pill taken three times daily with food for use with the other two drugs, peginterferon alpha and ribavirin. The approval came after the drug’s safety and efficacy were tested in two Phase 3 studies in 1500 s adult patients. The results of both studies showed that two thirds of patients taking the combination of three drugs had an SVR, which means that hepatitis C was not detected by blood tests, even six months after the end Treatment of an advance on the use of peginterferon and ribavirin alone.

SOURCES: May 13, 2011, press release, U. S. Food and Drug Administration, The New York Times

More information about hepatitis C to U. S. National Library of Medicine.

Victrelis, which is marketed by Merck New Jersey, is one of a class of drugs called protease inhibitors. These drugs work by binding with the virus and block its proliferation.

Victrelis is an important step forward for patients with hepatitis C, Dr. Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in a news agency. This new medicine allows an effective treatment for serious illness, and offers a greater chance of cure for some patients with hepatitis C infection compared to currently available treatments.

, and J.

Previous studies have shown that PDCs recognize HIV-1 using a receptor called Toll-like receptor 7 , leading to the production of interferon-alpha and other important molecules of the immune system.